Soleno Therapeutics, Inc.SLNONASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank46
5Y CAGR-9.9%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-9.9%/yr
Long-term compound
Percentile
P46
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 24.81% |
| 2024 | 685.26% |
| 2023 | 36.95% |
| 2022 | -8.90% |
| 2021 | 64.63% |
| 2020 | 41.68% |
| 2019 | -29.33% |
| 2018 | -0.82% |
| 2017 | -20.99% |
| 2016 | 6.20% |